RELOAD (Restriction Element Loss Of Allele Detection) is a precision oncology tool that detects a biomarker called HLA LOH (human leukocyte antigen loss of heterozygosity). Historically, HLA LOH has been a difficult biomarker to detect, but our scientific team invented a patent-pending method for detecting its occurrence in cancer patients. Our method does not require a solid biopsy, but instead, a standard blood draw holds the information needed for detecting HLA LOH. With this information, patients and their oncology team can make a more informed decision on whether immunotherapy is the correct treatment course.